BillionToOne, Inc.
BLLN
株式のランク
#3440
BillionToOne, Inc. is a specialized diagnostics company that innovates by... BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
株価
$103.00
時価総額
$4.86B
変化（1日）
-1.60%
変化（1年）
-
国
US
取引 BillionToOne, Inc. (BLLN)
カテゴリー
Healthcare
BillionToOne, Inc.（BLLN）の配当利回りの履歴
BillionToOne, Inc.（銘柄コード: BLLN）の配当利回り（TTM）は2024-12-31時点で0.00%です。
過去5年間の平均配当利回り: 0.00%
過去5年間の平均配当利回り: 0.00%
BillionToOne, Inc.（BLLN）の2023から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
| 年 | 配当利回り | 変化 |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
類似企業または競合他社の配当利回り（TTM）
| 企業 | 配当利回り | 国 |
|---|---|---|
| 0.27% |
US
|
|
| 0.65% |
US
|
|
| 0.00% |
US
|
|
| 1.48% |
CN
|
|
| 0.57% |
US
|
